References
1. Sakaguchi S, et al. Regulatory T Cells and Immune Tolerance.Cell . 2008;133(5):775-787.
2. Plitas G, Rudensky AY. Regulatory T cells: Differentiation and function. Cancer Immunol Res . 2016;4(9):721-725.
3. Atif M, et al. Regulatory T cells in solid organ transplantation. Clin Transl Immunol. 2020;9(2):1-15.
4. Guo WW, et al. Regulatory T Cells in GVHD Therapy. Front Immunol . 2021;12.
5. Esensten JH, et al. Regulatory T-cell therapy for autoimmune and autoinflammatory diseases: The next frontier. J Allergy Clin Immunol . 2018;142(6):1710-1718.
6. Raffin C, Vo LT, Bluestone JA. T reg cell-based therapies : challenges and perspectives. Nat Rev Immunol . 2021;20(3):158-172.
7. Mohseni YR, et al. The Future of Regulatory T Cell Therapy: Promises and Challenges of Implementing CAR Technology. Front Immunol . 2020;11:1-13.
8. Bluestone JA, et al. Type 1 diabetes immunotherapy using polyclonal regulatory T cells. Sci Transl Med . 2015;7(315).
9. Seddiki N, et al. Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J Exp Med . 2006;203(7):1693-1700.
10. Hoffmann P, et al. Large-scale in vitro expansion of polyclonal human CD4+CD25 high regulatory T cells. Blood . 2004;104(3):895-903.
11. Vignali D, et al. Detection and characterization of CD8 + autoreactive memory stem T cells in patients with type 1 diabetes.Diabetes . 2018;67:936-945.
12. Heninger A-K, et al. IL-7 abrogates suppressive activity of human CD4+ CD25 + FOXP3+ regulatory T cells and allows expansion of alloreactive and autoreactive T cells. J Immunol . 2012;189(12). 5649-5658
13. Vignali D, et al. IL-7 Mediated Homeostatic Expansion of Human CD4+CD25+FOXP3+ Regulatory T Cells After Depletion With Anti-CD25 Monoclonal Antibody. Transplantation . 2016;100(9). 1853-1861
14. Liu W, et al. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med . 2006;203(7):1701-1711. 15. Ryan BDH, et al. Expression of interleukin-7 receptor by lineage-negative human bone marrow progenitors with enhanced lymphoid proliferative potential and B-lineage differentiation capacity.Blood . 1997.89(3):929-940
16. Monti P, et al. Disengaging the IL-2 receptor with daclizumab enhances IL-7-mediated proliferation of CD4+ and CD8+ T Cells. Am J Transplant . 2009;9(12).2727-2735
17. Battaglia M, Stabilini A, Roncarolo MG. Rapamycin selectively expands CD4+CD25+FoxP3 + regulatory T cells. Blood . 2005;105(12):4743-4748.
18. Putnam AL, et al. Expansion of human regulatory T-cells from patients with type 1 diabetes. Diabetes . 2009;58(3):652-662.
19. MacDonald KN, Piret JM, Levings MK. Methods to manufacture regulatory T cells for cell therapy. Clin Exp Immunol . 2019;197(1):52-63.
20. Tan JT, et al. IL-7 is critical for homeostatic proliferation and survival of naïve T cells. Proc Natl Acad Sci U S A . 2001;98(15):8732-8737.
21. Chetoui N, et al. Interleukin-7 promotes the survival of human CD4+ effector/memory T cells by up-regulating Bcl-2 proteins and activating the JAK/STAT signalling pathway. Immunology . 2010;130(3):418-426.
22. Carrett F, Surh CD. IL-7 signaling and CD127 receptor regulation in the control of T cell homeostasis. Semin Immunol . 2012;24(3):209-217.
23. Gattinoni L, et al. A human memory T cell subset with stem cell-like properties. Nat Med. 2011;17(10):1290-1297.
24. Motwani K, et al. Human Regulatory T Cells From Umbilical Cord Blood Display Increased Repertoire Diversity and Lineage Stability Relative to Adult Peripheral Blood. Front Immunol . 2020;11:1-17.
25. Procaccini C, et al. An Oscillatory Switch in mTOR Kinase Activity Sets Regulatory T Cell Responsiveness. Immunity . 2010;33(6):929-941.
26. Angelin A, et al. Foxp3 Reprograms T Cell Metabolism to Function in Low-Glucose, High-Lactate Environments. Cell Metab . 2017;25(6):1282-1293.e7.
27. Garriets VA et al. Foxp3 and Toll-Like Receptor Signaling Balance Treg Cell Anabolic Metabolism for Suppression. Nat Immunol . 2016;17(12):1459-1466
28. Shi, et al. HIF1α-dependent glycolytic pathway orchestrates a metabolic checkpoint for the differentiation of TH17 and Treg cells.J Exp Med . 2011;208(7):1367-1376.
29. Pacella I, et al. Fatty acid metabolism complements glycolysis in th selective regulatory t cell expansion during tumor growth. Proc Natl Acad Sci U S A. 2018;115(28):E6546-E6555.
30. Kishore M, et al. Regulatory T Cell Migration Is Dependent on Glucokinase-Mediated Glycolysis. Immunity . 2017;47(5):875-889
31. Fritzsching B, et al. Naive regulatory T cells: A novel subpopulation defined by resistance toward CD95L-mediated cell death.Blood . 2006;108(10):3371-3378.
32. Patrick MS, Cheng NL, Kim J, et al. Human T cell differentiation negatively regulates telomerase expression resulting in reduced activation-induced proliferation and survival. Front Immunol . 2019;10:1-11
1. Sakaguchi S, et al. Regulatory T Cells and Immune Tolerance.Cell 2008;133(5):775–787.
2. Plitas G, Rudensky AY. Regulatory T cells: Differentiation and function. Cancer Immunol. Res. 2016;4(9):721–725.
3. Atif M, et al. Regulatory T cells in solid organ transplantation.Clin. Transl. Immunol. 2020;9(2):1–15.
4. Guo WW, et al. Regulatory T Cells in GVHD Therapy. Front. Immunol. 2021;12(June). doi:10.3389/fimmu.2021.697854
5. Esensten JH, et al. Regulatory T-cell therapy for autoimmune and autoinflammatory diseases: The next frontier. J. Allergy Clin. Immunol. 2018;142(6):1710–1718.
6. Raffin C, Vo LT, Bluestone JA. T reg cell-based therapies : challenges and perspectives2021;20(3):158–172.
7. Mohseni YR, et al. The Future of Regulatory T Cell Therapy: Promises and Challenges of Implementing CAR Technology. Front. Immunol.2020;11(July):1–13.
8. Bluestone JA, et al. Type 1 diabetes immunotherapy using polyclonal regulatory T cells2015;7(315).
9. Seddiki N, et al. Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J. Exp. Med. 2006;203(7):1693–1700.
10. Hoffmann P, et al. Large-scale in vitro expansion of polyclonal human CD4+CD25 high regulatory T cells. Blood2004;104(3):895–903.
11. Vignali D, et al. Detection and characterization of CD8 + autoreactive memory stem T cells in patients with type 1 diabetes.Diabetes 2018;67(May):936–945.
12. Heninger A-K, et al. IL-7 abrogates suppressive activity of human CD4+ CD25 + FOXP3+ regulatory T cells and allows expansion of alloreactive and autoreactive T cells. J. Immunol. 2012;189(12). doi:10.4049/jimmunol.1201286
13. Vignali D, et al. IL-7 Mediated Homeostatic Expansion of Human CD4+CD25+FOXP3+ Regulatory T Cells After Depletion With Anti-CD25 Monoclonal Antibody2016;100(9). doi:10.1097/TP.0000000000001276
14. Liu W, et al. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J. Exp. Med.2006;203(7):1701–1711.
15. Ryan BDH, et al. and B-Lineage Differentiation Capacity1997;
16. Monti P, et al. Disengaging the IL-2 receptor with daclizumab enhances IL-7-mediated proliferation of CD4+ and CD8+ T Cells. Am. J. Transplant. 2009;9(12). doi:10.1111/j.1600-6143.2009.02825.x
17. Battaglia M, Stabilini A, Roncarolo MG. Rapamycin selectively expands CD4+CD25+FoxP3 + regulatory T cells. Blood2005;105(12):4743–4748.
18. Putnam AL, et al. Expansion of human regulatory T-cells from patients with type 1 diabetes. Diabetes 2009;58(3):652–662.
19. MacDonald KN, Piret JM, Levings MK. Methods to manufacture regulatory T cells for cell therapy. Clin. Exp. Immunol.2019;197(1):52–63.
20. Tan JT, et al. IL-7 is critical for homeostatic proliferation and survival of naïve T cells. Proc. Natl. Acad. Sci. U. S. A.2001;98(15):8732–8737.
21. Chetoui N, et al. Interleukin-7 promotes the survival of human CD4+ effector/memory T cells by up-regulating Bcl-2 proteins and activating the JAK/STAT signalling pathway. Immunology 2010;130(3):418–426.
22. Manuscript A. NIH Public Access2013;24(3):209–217.
23. Gattinoni L, et al. A human memory T cell subset with stem cell-like properties. Nat. Med. 2011;17(10):1290–1297.
24. Motwani K, et al. Human Regulatory T Cells From Umbilical Cord Blood Display Increased Repertoire Diversity and Lineage Stability Relative to Adult Peripheral Blood. Front. Immunol. 2020;11(April):1–17.
25. Procaccini C, et al. An Oscillatory Switch in mTOR Kinase Activity Sets Regulatory T Cell Responsiveness. Immunity2010;33(6):929–941.
26. Angelin A, et al. Foxp3 Reprograms T Cell Metabolism to Function in Low-Glucose, High-Lactate Environments. Cell Metab.2017;25(6):1282-1293.e7.
27. Issa F. Foxp3 and Toll-Like Receptor Signaling Balance Treg Cell Anabolic Metabolism for Suppression. Transplantation2017;101(2):218.
28. Shi LZ, et al. HIF1α-dependent glycolytic pathway orchestrates a metabolic checkpoint for the differentiation of TH17 and Treg cells.J. Exp. Med. 2011;208(7):1367–1376.
29. Pacella I, et al. Fatty acid metabolism complements glycolysis in th selective regulatory t cell expansion during tumor growth. Proc. Natl. Acad. Sci. U. S. A. 2018;115(28):E6546–E6555.
30. Kishore M, et al. Regulatory T Cell Migration Is Dependent on Glucokinase-Mediated Glycolysis. Immunity 2017;47(5):875-889.e10.
31. Fritzsching B, et al. Naive regulatory T cells: A novel subpopulation defined by resistance toward CD95L-mediated cell death.Blood 2006;108(10):3371–3378.
32. Patrick MS, et al. Human T cell differentiation negatively regulates telomerase expression resulting in reduced activation-induced proliferation and survival. Front. Immunol. 2019;10(AUG):1–11.